AJR Am J Roentgenol
- SHETTY AS
The Complementary Value of Prostate Bed MRI After a Negative PSMA PET/CT
Examination in Prostate Cancer Biochemical Recurrence.
AJR Am J Roentgenol. 2026 Jul 22. doi: 10.2214/AJR.26.35584.
Br J Cancer
- TIEFENBACHER A, Gudenus M, Valcanover D, Neudert B, et al
Adipose triglyceride lipase driven lipolysis as a targetable metabolic
vulnerability in prostate cancer with intrinsic metabolic inflexibility.
Br J Cancer. 2026 Jul 23. doi: 10.1038/s41416-026-03545.
Br J Radiol
- VELLA A, Padmanaban S, Robinson M
Development and implementation of Automated Clinical Treatment Planning (ACT) for
routine prostate and breast treatments.
Br J Radiol. 2026;99:1558-1568.
Cancer Lett
- WILLIAMS EC, Shibata M
Prostate luminal cell plasticity and cancer.
Cancer Lett. 2025;611:217430.
Clin Cancer Res
- TAGAWA ST, Thomas C, Arham AB, Holmes A, et al
A phase I dose-escalation/expansion study of fractionated-dose and multiple cycle
anti-PSMA-targeted alpha emitter 225Ac-J591 in patients with prostate cancer.
Clin Cancer Res. 2026 Jul 22. doi: 10.1158/1078-0432.CCR-26-0689.
Eur Urol
- BLANCHARD P, Sighinolfi C, Terlizzi M, Rocco B, et al
Five-Year Patient-Reported Outcomes After SBRT for Prostate Cancer: A Benchmark
for Radiotherapy, but How Far Across Modalities?
Eur Urol. 2026 Jul 24:S0302-2838(26)02300-6. doi: 10.1016/j.eururo.2026.
- MORTEZAVI A, van der Hulle T, van den Bergh R
What Comes After Matters: The Importance of Postprogression Care in Patients with
Metastatic Hormone-sensitive Prostate Cancer.
Eur Urol. 2026 Jul 23:S0302-2838(26)02258-X. doi: 10.1016/j.eururo.2026.
- ULERI A, Baboudjian M, Lughezzani G, Ploussard G, et al
Re: James P. Buteau, Daniel Moon, Michael T. Fahey, et al. Effect of
[(68)Ga]Ga-PSMA-11 PET-CT in the Diagnosis of Prostate Cancer in Men with
Equivocal or Clinically High-risk Non-suspicious Findings on Multiparametric MRI
(PRIMARY2): A Multicenter,
Eur Urol. 2026 Jul 23:S0302-2838(26)02269-4. doi: 10.1016/j.eururo.2026.
- KIM JS, Chang AR, Kim JH
Re: Robert M. Meier, Nima Aghdam, Alan C. Beckman et al. 10-yr Survival and
Toxicity Outcomes of Stereotactic Body Radiotherapy for Prostate Cancer: A
Nonrandomized Clinical Trial. Eur Urol In press.
http://dx.doi.org/10.1016/j.eururo.2026.04.029.
Eur Urol. 2026 Jul 23:S0302-2838(26)02276-1. doi: 10.1016/j.eururo.2026.
- NGUYEN DD, Najafabadi BT, Lin L, Kwong JCC, et al
Reply to J.H. Kim and Y.S. Shin's Letter to the Editor re: Re: Effect of Prostate
Cancer Screening with Prostate-specific Antigen Testing on Long-term Prostate
Cancer-specific Mortality: A Systematic Review and Meta-analysis of Randomized
Controlled T
Eur Urol. 2026 Jul 21:S0302-2838(26)02272-4. doi: 10.1016/j.eururo.2026.
Int J Cancer
- BOTTING-PROVOST S, Ng K, Laurie C, Noorani R, et al
The Association Between Human Papillomavirus and Prostate Cancer: A Systematic
Review and Meta-Analysis.
Int J Cancer. 2026 Jul 21. doi: 10.1002/ijc.70663.
Int J Radiat Oncol Biol Phys
- TAKAYESU JSK, Xie T, Aldous J, Nasser B, et al
ADT combinations with radiation for prostate cancer: A systematic review and
meta-analysis.
Int J Radiat Oncol Biol Phys. 2026 Jul 19:S0360-3016(26)04013.
Int J Urol
- MITA Y, Teishima J, Ueki H, Wakita N, et al
Effects of Modifying Hinotori Surgical Robot System on the Learning Curve of
Robot-Assisted Radical Prostatectomy.
Int J Urol. 2026;33:e70577.
- HATA K, Goto Y, Hashimoto M, Okamoto M, et al
Bleeding Events Associated With Continuing Antithrombotic Therapy During
Transrectal Ultrasound-Guided Prostate Biopsy: A Propensity Score-Matched
Analysis.
Int J Urol. 2026;33:e70580.
J Nucl Med
- KARIMZADEH A, Futterer C, Hansen K, Coban O, et al
Outcome Prediction After [(177)Lu]Lu-PSMA I&T in Metastatic Castration-Resistant
Prostate Cancer: External Validation of a [(68)Ga]Ga-PSMA-11 PET-Based Model with
[(18)F]F-Flotufolastat.
J Nucl Med. 2026 Jul 23:jnumed.125.270944. doi: 10.2967/jnumed.125.270944.
Oncogene
- WANG KJ, Wang KY, Chen SX, Ma YT, et al
RON receptor tyrosine kinase regulates abiraterone resistance in prostate cancer
via the methylation-dependent and independent dual functions of DNMT1.
Oncogene. 2026 Jul 24. doi: 10.1038/s41388-026-03906.
PLoS One
- NAKAJIMA N, Kazama T, Takahara T, Oda K, et al
Efficacy and limitations of diffusion-weighted imaging with background
suppression-based whole-body magnetic resonance imaging in high-risk prostate
cancer staging: A retrospective study.
PLoS One. 2026;21:e0354601.
- YOON E, Cho JD, Choi CH, Kim JH, et al
In vivo rectal dosimeter with MRI marker.
PLoS One. 2026;21:e0354149.
Proc Natl Acad Sci U S A
- GUAN H, Mao L, Fang F, Wu T, et al
ZNF263-NuRD-mediated repression of STAT1 curtails MHC-I antigen presentation and
IFN-gamma efficacy in prostate cancer.
Proc Natl Acad Sci U S A. 2026;123:e2603231123.
Prostate
- GONZALEZ-MARTINEZ CA, Alcacio-Mendoza JA, Hernandez-Ramirez R, Lagos-Beitz HE, et al
Intense Focal Peripheral Uptake Pattern on 18F-PET/PSMA as a Predictor of
Histological Upgrading in Prostate Cancer.
Prostate. 2026 Jul 23. doi: 10.1002/pros.70220.
- SUZUKI K, Hirata J, Ueki H, Wakita N, et al
Prognostic Significance of the Modified Glasgow Prognostic Score and Systemic
Immune-Inflammation Index in Patients With Metastatic Castration-Resistant
Prostate Cancer Treated With Cabazitaxel.
Prostate. 2026 Jul 19. doi: 10.1002/pros.70227.
- TANAKA Y, Shimizu F, Abudurezake A, Diabangouaya M, et al
Enhancing Continence Recovery After Robot-Assisted Radical Prostatectomy: A Novel
Combined Approach Using Testosterone Therapy and Magnetic Stimulation.
Prostate. 2026 Jun 9. doi: 10.1002/pros.70205.
- FURUMIDO J, Nonoyama S, Hoshi C (Hosokawa), Aizawa S, et al
Real-World Clinical Evaluation of S2,3PSA Test in a Prostate Biopsy Cohort With
PSA Level of 4-10 ng/mL.
Prostate. 2026;86:1258-1262.
Free Medical Abstracts
Privacy Policy
Sponsors
Share
© Amedeo 1997-2016